藥捷安康

Frontier Biopharma is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, focused on the discovery and development of innovative small molecule drugs. The company targets high-unmet-need areas in oncology, immunology, and liver diseases through its proprietary drug discovery platform. Its lead asset, tinengotinib (TT-00420), is a multi-kinase inhibitor currently in Phase 3 registrational trials for cholangiocarcinoma and Phase 2 for other solid tumors. Frontier Biopharma has established strategic partnerships with global and domestic leaders, including LG Chem and Fosun Pharma, to accelerate the development of its pipeline. The company's R&D engine continues to produce a diverse range of candidates, including inhibitors for SSAO/VAP-1 and MEK. Tinengotinib has received Fast Track Designation from the U.S. FDA, highlighting its potential as a first-in-class therapy.